About: Timing and delay of radical prostatectomy do not lead to adverse oncologic outcomes: results from a large European cohort at the times of COVID-19 pandemic

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Timing and delay of radical prostatectomy do not lead to adverse oncologic outcomes: results from a large European cohort at the times of COVID-19 pandemic Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Timing and delay of radical prostatectomy do not lead to adverse oncologic outcomes: results from a large European cohort at the times of COVID-19 pandemic
Creator	Damme, Van Albisinni, · Benamran, Daniel Descotes, Jean-Luc Diamand, Romain Fiard, · Iselin, Christophe Julien, · Malavaud, · Oderda, Marco Peltier, Alexandre Ploussard, · Roche, Jean-Baptiste Roumiguié, · Simone, Giuseppe Thierry Quackels, · Thierry Roumeguère, ·
source	Medline; PMC
abstract	PURPOSE: The current COVID-19 pandemic is transforming our urologic practice and most urologic societies recommend to defer any surgical treatment for prostate cancer (PCa) patients. It is unclear whether a delay between diagnosis and surgical management (i.e., surgical delay) may have a detrimental effect on oncologic outcomes of PCa patients. The aim of the study was to assess the impact of surgical delay on oncologic outcomes. METHODS: Data of 926 men undergoing radical prostatectomy across Europe for intermediate and high-risk PCa according to EAU classification were identified. Multivariable analysis using binary logistic regression and Cox proportional hazard model tested association between surgical delay and upgrading on final pathology, lymph-node invasion (LNI), pathological locally advanced disease (pT3–4 and/or pN1), need for adjuvant therapy, and biochemical recurrence. Kaplan–Meier analysis was used to estimate BCR-free survival after surgery as a function of surgical delay using a 3 month cut-off. RESULTS: Median follow-up and surgical delay were 26 months (IQR 10–40) and 3 months (IQR 2–5), respectively. We did not find any significant association between surgical delay and oncologic outcomes when adjusted to pre- and post-operative variables. The lack of such association was observed across EAU risk categories. CONCLUSION: Delay of several months did not appear to adversely impact oncologic results for intermediate and high-risk PCa, and support an attitude of deferring surgery in line with the current recommendation of urologic societies.
has issue date	2020-08-10(xsd:dateTime)
bibo:doi	10.1007/s00345-020-03402-w
bibo:pmid	32776243
has license	no-cc
sha1sum (hex)	b2a0456245fbf7c111cd8eb68743846b2ceb9f7b
schema:url	https://doi.org/10.1007/s00345-020-03402-w
resource representing a document's title	Timing and delay of radical prostatectomy do not lead to adverse oncologic outcomes: results from a large European cohort at the times of COVID-19 pandemic
has PubMed Central identifier	PMC7416303
has PubMed identifier	32776243
schema:publication	World J Urol
resource representing a document's body	covid:b2a0456245fbf7c111cd8eb68743846b2ceb9f7b#body_text
is schema:about of	named entity 'surgery' named entity 'patients' named entity 'delay' named entity 'pathology' named entity 'COVID-19' named entity 'impact' named entity 'surgical' named entity 'prostate cancer' named entity 'aim' named entity 'estimate' named entity 'delay' named entity 'intermediate' named entity 'IQR' named entity 'proportional' named entity 'large' named entity 'TIMES' named entity 'LARGE' named entity 'TIMING' named entity 'COVID-19 PANDEMIC' named entity 'PCa' named entity 'urologic' named entity 'prostatectomy' named entity 'upgrading' named entity 'surgical' named entity 'impact' named entity 'variables' named entity 'logistic regression' named entity 'diagnosis' named entity 'pandemic' named entity 'high-risk' named entity 'locally advanced' named entity 'high-risk' named entity 'biochemical recurrence' named entity 'proportional hazard model' named entity 'pathology' named entity 'COVID-19 pandemic' named entity 'PCa' named entity 'LNI' named entity 'imaging modality' named entity 'MRI' named entity 'MRI' named entity 'La Tronche' named entity 'transrectal ultrasound' named entity 'confidence interval' named entity 'biopsy' named entity 'surgical treatment' named entity 'surgical planning' named entity 'radiologists' named entity 'biopsy' named entity 'Belgium' named entity 'probability' named entity 'urologists' named entity 'high-risk' named entity 'magnetic resonance imaging' named entity 'multivariable analysis' named entity 'LNI' named entity 'clinical practice' named entity 'neoadjuvant therapy' named entity 'Switzerland' named entity 'log-rank test' named entity 'Biochemical recurrence' named entity 'PET' named entity '1.02' named entity 'PI-RADS' named entity 'imaging modalities'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software